The most commonly used immunotherapies for lung cancer block the interaction between PD1 and PDL1, and recent clinical trials suggested that anti-CTLA4 and anti-PD1 combination therapy improved the survival of patients independent of tumour PD1 expression31,32. Here, CTLA4 is linked to lung carcinoma.